News

A retrospective study found an independent association between increased pain episodes in sickle cell disease and the cold in light of increasingly extreme weather.

In this segment of a Liver Lineup episode, experts discuss where the new US Dietary Guidelines miss the mark for alcohol recommendations.

A prospective study finds adolescents with MDD show faster response, fewer cognitive effects, and better tolerability with magnetic seizure therapy than adults.

Friedmann describes his research exploring the benefits of mobile telemedicine for HCV infection among persons who inject drugs in rural areas.

FLOW/SELECT suggest. GLP-1 receptor agonists may protect kidneys beyond glucose control

These positive results of Ameluz photodynamic therapy suggest the treatment is effective in actinic keratoses on the neck, trunk, and extremities.

Hardy discussed the disparity between treatment access and usage, highlighting the fact that most patients are within 10 mmHg of guideline recommendations.

An audio recap of the top 5 stories in healthcare news from the week of 02/01-02/07.

This Q&A interview with Philip Mease, MD, highlights his contribution to the ‘Psoriasis Update 2026’ talk given at the 2026 Maui Derm Hawaii meeting.

Stay updated with the latest healthcare breakthroughs, including topline phase 2 data, FDA actions, and regulatory submissions, in this week’s essential news roundup.

This FDA News Month in Review provides a round-up of regulatory decisions from January 2026.

Ruff explains his prespecified analysis of the phase 2b AZALEA-TIMI 71 trial, highlighting abelacimab’s efficacy and durability compared to rivaroxaban.

Investigators assessed the efficacy of switching to upadacitinib in those with atopic dermatitis who had an inadequate response to dupilumab.

The 2024 global update for urticaria preserves the stepwise algorithm and clarifies evidence on biomarkers, provocation testing, pediatric care, and emerging therapies.

Despite an FDA CRL over usability, trial data suggest the needle-free epinephrine film rivals autoinjectors in speed and absorption, with promise for real-world readiness.

Hovanesian breaks down the process by which Yuvezzi received FDA approval and discusses the prescription and application of the new drug.

The 2025 KDIGO guidelines guide mechanism-driven therapy in IgA nephropathy, highlighting targeted interventions across the 4-hit disease cascade.

Catch up on dermatology news from January 2026, expert insights on dermatologic disease management, and more.

This segment of Liszewski’s interview at Maui Derm Hawaii 2026 highlights additional takeaways for clinicians regarding the treatment of contact dermatitis.

New data presented at EHSF in Malta boasts a reduced proportion of patients with severe HS at 3 years.

Tegoprubart, a CD40L-targeted therapy, may improve long-term kidney transplant outcomes by reducing immune-mediated injury.

The DROP-FPF Phase 3b trial will use automated HRCT biomarkers to assess whether early treatment with nerandomilast can slow disease progression before lung function declines.

Russman highlights asundexian’s efficacy in patients following a non-cardioembolic ischemic stroke or high-risk transient ischemic attack.

2025 KDIGO guidelines reshape IgA nephropathy care with earlier biopsy, tighter proteinuria targets, and personalized treatment strategies.

Vaginal delivery, exclusive breastfeeding, and early sibling exposure strongly predicted colonization with bifidobacteria that suppress IgE responses in a recent study.

New study shows baseline impulsivity links to residual symptoms but not relapse, highlighting the need for individualized, clinician-guided decisions.

In the final segment, experts discuss how to navigate traditional or cultural foods with patients in the absence of their inclusion in the guidelines.

In part 7 of the discussion, experts reflect on access issues regarding foods recommended in the guidelines.